Alkermes Thinks Nemvaleukin Could Succeed Where Other IL-2 Candidates Have Failed

 
• By Joseph Haas

On the heels of clinical failures for Nektar’s pegylated IL-2 candidate bempeg, Alkermes’ CEO argued its high-dose IL-2 for cancer is well differentiated during earnings call. Schizophrenia drug Lybalvi posted solid first full-quarter revenue, prescription numbers.

Differentiation
Alkermes stressed the differences between its nemvaleukin and other IL-2 candidates • Source: Alamy

With Alkermes plc reporting its first quarter earnings just days after rival Nektar Therapeutics announced a restructuring due to failed clinical trials for its IL-2 candidate bempegaldesleukin, CEO Richard Pops was prepared to face questions about Alkermes’ high-dose interleukin-2 candidate nemvaleukin – and argued nemvaleukin could be poised to succeed in an area where previous candidates have not.

“We've been … saying the correlation between nemvaleukin and bempeg is extremely limited,” the CEO said in an interview

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business